The clinical pharmacology of alkylating agents in high-dose chemotherapy
Authors:
- Alwin Dr HuitemaAlwin Dr Huitema
- Karen Doesburg SmitsKSKaren Doesburg Smits
- Ron Aa MathôtRMRon Aa Mathôt
- Jan Hm SchellensJSJan Hm Schellens
- Sjoerd RodenhuisSRSjoerd Rodenhuis
- Jos H BeijnenJBJos H Beijnen
- 1 August 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 11 (7) , 515-533
Abstract
Alkylating agents are widely used in high-dose chemotherapy regimens in combination with hematological support. Knowledge about the pharmacokinetics and pharmacodynamics of these agents administered in high doses is critical for the safe and efficient use of these regimens. The aim of this review is to summarize the clinical pharmacology of the alkylating agents (including the platinum compounds) in high-dose chemotherapy. Differences between conventional and high doses will be discussed.Keywords
This publication has 140 references indexed in Scilit:
- A mechanism‐based pharmacokinetic‐enzyme model for cyclophosphamide autoinduction in breast cancer patientsBritish Journal of Clinical Pharmacology, 1999
- High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4–9 involved axillary lymph nodesBone Marrow Transplantation, 1997
- An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in childrenBone Marrow Transplantation, 1997
- A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicityBritish Journal of Haematology, 1996
- Glutathione Conjugation of the Cytostatic Drug Ifosfamide and the Role of Human Glutathione S-TransferasesChemical Research in Toxicology, 1995
- Hemorrhagic Cystitis Complicating Bone Marrow TransplantationMayo Clinic Proceedings, 1992
- Pharmacokinetically guided dosing for intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinomaEuropean Journal of Cancer, 1992
- Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolitesCancer Chemotherapy and Pharmacology, 1987
- Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patientsCancer Chemotherapy and Pharmacology, 1987
- Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer a phase I-II studyCancer, 1983